example 31 [WO2018183145]   Click here for help

GtoPdb Ligand ID: 12666

Compound class: Synthetic organic
Comment: This compound is claimed in patent WO2018183145A1, as a small molecule modulator of GRP6 activity [1]. It is likely an antagonist or inverse agonist that reduces GPR6-regulated intracellular cAMP levels. Antagonism of GPR6 activity is being explored clinically, as a functional alternative to dopamine mediated activation of D2 receptors for conditions such as Parkinson's disease and other dyskinesias.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 1
Rotatable bonds 9
Topological polar surface area 95.83
Molecular weight 511.52
XLogP 1.25
No. Lipinski's rules broken 1
Click here for help
Isomeric SMILES FC1=C(OC2CCN(CC2)C3=CC(=NC=C3NC(C4=C(N=CC=C4)OC)=O)C(=O)N(C)C)C=CC(=C1)F
InChI InChI=1S/C26H27F2N5O4/c1-32(2)26(35)20-14-22(21(15-30-20)31-24(34)18-5-4-10-29-25(18)36-3)33-11-8-17(9-12-33)37-23-7-6-16(27)13-19(23)28/h4-7,10,13-15,17H,8-9,11-12H2,1-3H3,(H,31,34)
Bioactivity Comments
Example 31 reverses haloperidol-induced catalepsy (a mouse Parkinson's disease model) in vivo, by 47% [1].
Selectivity at GPCRs
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
GPR6 Hs Agonist Inverse agonist 7.1 pEC50 - 1
pEC50 7.1 (EC50 7.94x10-8 M) [1]
Description: Inhibition of GPR6 constitutive cAMP activity in CHO-K1 cells.